Similar articles

• Is the use of t-PA as compared with streptokinase cost effective?

  Armentano R, Favaloro RG. Armentano R, et al. N Engl J Med. 1995 Oct 12;333(15):1009-10. N Engl J Med. 1995. PMID: 7666905 No abstract available.
• Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.

  Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL. Mark DB, et al. N Engl J Med. 1995 May 25;332(21):1418-24. doi: 10.1056/NEJM199505253322106. N Engl J Med. 1995. PMID: 7723799
• Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.

  Kent DM, Vijan S, Hayward RA, Griffith JL, Beshansky JR, Selker HP. Kent DM, et al. J Clin Epidemiol. 2004 Aug;57(8):843-52. doi: 10.1016/j.jclinepi.2004.01.008. J Clin Epidemiol. 2004. PMID: 15485737
• Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.

  Massel D. Massel D. Can J Cardiol. 1999 Feb;15(2):173-9. Can J Cardiol. 1999. PMID: 10079776 Review.
• [Myocardial infarction treated within 4 hrs: comparison of the cost-benefit ratio of 3 thrombolytic treatments: APSAC, rt-PA and streptokinase in 270 patients].

  Machecourt J, Cassagnes J, Bassand JP, Dumoulin J, Calop J, Foroni L, Terrisse MP, Hénon T, Petit L, Denis B. Machecourt J, et al. Arch Mal Coeur Vaiss. 1993 Feb;86(2):209-17. Arch Mal Coeur Vaiss. 1993. PMID: 8363422 Review. French.